UPDATE 2-Roche cancer treatment priced at $17,050 a month, lower than rival Vitrakvi
August 16, 2019 at 16:44 PM EDT
Roche Holding AG has priced its personalized cancer treatment, Rozlytrek, at about $17,050 per month, nearly half of the monthly price of a rival drug from Bayer AG and Eli Lilly and Co that was approved last year.